Primary mesonephric adenocarcinoma of the fallopian tube: A case report

paythelady.612 shared this article with you from Inoreader Primary mesonephric adenocarcinoma of the fallopian tube: A case report Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jun 26;9(18):4741-4747. doi: 10.12998/wjcc.v9.i18.4741. ABSTRACT BACKGROUND: Mesonephric adenocarcinoma (MNAC) is an extremely rare malignancy in the female genital tract. Only a few cases have been reported in the literature, and most of them occurred in the cervix, with extremely rare cases in the uterine body and ovary. MNAC has never been reported to arise in the fallopian tube. CASE SUMMARY: A 45-year-old woman was referred to our institution with a history of abdominal pain. Ultrasound revealed a cystic and solid mass in left adnexal region. The patient underwent complete staging surgery when intraoperative pathological examination demonstrated that the mass was malignant. The final histological and immunohistochemical results confirmed the diagnosis of MNAC originating from the fallopian tube. Then she received four cycles of combination chemotherapy with carboplatin plus paclitaxel. The tumor recu rred with hepatic metastases 4 mo after initial surgery, and second resection of the tumors in the liver plus partial hepatectomy was performed. She was supplemented with five courses of a new combination chemotherapy with gemcitabine plus carboplatin, and there was no evidence of recurrence within the 22-mo follow-up period after the second surgery. CONCLUSION: MNAC originating from the fallopian tube is an extremely rare and high malignancy with a poor prognosis. It can be very aggressive, even at early stage. Little is known about the clinical characteristics, pathological diagnosis, prognosis, and optimal management strategy of MNAC originating from the fallopian tube. Herein we report the first case of primary MNAC deriving from the fallopian tube. PMID:34222441 | PMC:PMC8223862 | DOI:10.12998/wjcc.v9.i18.4741 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.